Skip to main content
SpringerLink
Log in

Psoriasis

  • Chapter
Psoriasis and Psoriatic Arthritis

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192: 681–694

    Article  PubMed  CAS  Google Scholar 

  2. Ackermann L, Harvima IT, Pelkonen J, Ritamaki-Salo V, Naukkarinen A, Harvima RJ, Horsmanheimo M (1999) Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br J Dermatol 140: 624–633

    Article  PubMed  CAS  Google Scholar 

  3. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745–756

    Article  PubMed  CAS  Google Scholar 

  4. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL (2003) Interleukin-23 promotes a distinct CD4T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910–1914

    Article  PubMed  CAS  Google Scholar 

  5. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G (2000) Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma-and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 115: 81–87

    Article  PubMed  CAS  Google Scholar 

  6. Alegre ML, Frauwirth KA, Thompson CB (2001) Tcell regulation by CD28 and CTLA-4. Nat Rev Immunol 1: 220–228

    Article  PubMed  CAS  Google Scholar 

  7. Anton v.d. M, Davis SJ, Shaw AS, Dustin ML (2000) Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin Immunol 12: 5–21

    Google Scholar 

  8. Antoni C, Manger B (2002) Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 20: S122–S125

    PubMed  CAS  Google Scholar 

  9. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101: 783–794

    PubMed  CAS  Google Scholar 

  10. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113: 752–759

    Article  PubMed  CAS  Google Scholar 

  11. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J (1998) Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 38: 938–944

    Article  PubMed  CAS  Google Scholar 

  12. Baker BS, Griffiths CE, Lambert S, Powles AV, Leonard JN, Valdimarsson H, Fry L (1987) The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 116: 503–510

    PubMed  CAS  Google Scholar 

  13. Baker BS, Brown DW, Fischetti VA, Ovigne JM, Porter W, Powles A, Fry L (2001) Skin T cell proliferative response to M protein and other cell wall and membrane proteins of group A streptococci in chronic plaque psoriasis. Clin Exp Immunol 124: 516–521

    Article  PubMed  CAS  Google Scholar 

  14. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245–252

    Article  PubMed  CAS  Google Scholar 

  15. Barker JN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ (1991a) Detection of interferongamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci 2: 106–111

    Article  PubMed  CAS  Google Scholar 

  16. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ (1991b) Keratinocytes as initiators of inflammation. Lancet 337: 211–214

    PubMed  CAS  Google Scholar 

  17. Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14: 303–313

    Article  PubMed  CAS  Google Scholar 

  18. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J, Whitmore TE, Yao L, Kuechle MK, Dale BA, Chandrasekher YA (2001) Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9–19

    Article  PubMed  CAS  Google Scholar 

  19. Boehncke WH, Dressel D, Zollner TM, Kaufmann R (1996) Pulling the trigger on psoriasis. Nature 379: 777

    Article  PubMed  CAS  Google Scholar 

  20. Boehncke WH, Kock M, Hardt-Weinelt K, Wolter M, Kaufmann R (1999) The SCID-hu xenogeneic transplantation model allows screening of antipsoriatic drugs. Arch Dermatol Res 291: 104–106

    PubMed  CAS  Google Scholar 

  21. Boehncke WH, Hardt-Weinelt K, Nilsson H, Wolter M, Dohlsten M, Ochsendorf FR, Kaufmann R, Antonsson P (2001) Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model. J Invest Dermatol 116: 596–601

    Article  PubMed  CAS  Google Scholar 

  22. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, Porcelli SA, Nickoloff BJ (2000) Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 165: 4076–4085

    PubMed  CAS  Google Scholar 

  23. Borel JF, Gunn HC (1986) Cyclosporine as a new approach to therapy of autoimmune diseases. Ann N Y Acad Sci 475: 307–319

    PubMed  CAS  Google Scholar 

  24. Bos JD (1988) The pathomechanisms of psoriasis; the skin immune system and cyclosporin. Br J Dermatol 118: 141–155

    PubMed  CAS  Google Scholar 

  25. Bos WH, Farber EM (1997) Joseph Stalin’s psoriasis: its treatment and the consequences. Cutis 59: 197–199

    PubMed  CAS  Google Scholar 

  26. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez-Vina MA, Menter A (2001) Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 10: 1793–1805

    Article  PubMed  CAS  Google Scholar 

  27. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha}. J Exp Med 199: 731–736

    Article  PubMed  CAS  Google Scholar 

  28. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (2001) The immunological synapse. Annu Rev Immunol 19: 375–396

    Article  PubMed  CAS  Google Scholar 

  29. Brown DW, Baker BS, Ovigne JM, Hardman C, Powles AV, Fry L (2000) Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol 114: 576–580

    Article  PubMed  CAS  Google Scholar 

  30. Capon F, Munro M, Barker J, Trembath R (2002) Searching for the major histocompatibility complex psoriasis susceptibility gene. J Invest Dermatol 118: 745–751

    Article  PubMed  CAS  Google Scholar 

  31. Cooley HM, Snowden JA, Grigg AP, Wicks IP (1997) Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum 40: 1712–1715

    PubMed  CAS  Google Scholar 

  32. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J, Robinson J, Nickoloff BJ (2003a) Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 127: 178–186

    PubMed  CAS  Google Scholar 

  33. Curry JL, Qin JZ, Robinson J, Nickoloff BJ (2003b) Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch Pathol Lab Med 127: 289–296

    PubMed  Google Scholar 

  34. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ (1999) 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 113: 1082–1089

    Article  PubMed  CAS  Google Scholar 

  35. Dustin ML, Colman DR (2002) Neural and immunological synaptic relations. Science 298: 785–789

    Article  PubMed  CAS  Google Scholar 

  36. Dustin ML, Springer TA (1988) Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107: 321–331

    Article  PubMed  CAS  Google Scholar 

  37. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345: 248–255

    Article  PubMed  CAS  Google Scholar 

  38. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG (1991) Cyclosporine for plaquetype psoriasis. Results of a multidose, doubleblind trial. N Engl J Med 324: 277–284

    Article  PubMed  CAS  Google Scholar 

  39. European FK 506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132: 419–423

    Google Scholar 

  40. Farber EM, Nickoloff BJ, Recht B, Fraki JE (1986) Stress, symmetry, and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 14: 305–311

    PubMed  CAS  Google Scholar 

  41. Gerlini G, Hefti HP, Kleinhans M, Nickoloff BJ, Burg G, Nestle FO (2001) Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol 117: 576–582

    Article  PubMed  CAS  Google Scholar 

  42. Ghoreschi K, Mrowietz U, Rocken M (2003) A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 81: 471–480

    Article  PubMed  CAS  Google Scholar 

  43. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS (1997) T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 109: 283–288

    Article  PubMed  CAS  Google Scholar 

  44. Gilhar A, Ullmann Y, Kerner H, Assy B, Shalaginov R, Serafimovich S, Kalish RS (2002) Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 119: 384–391

    Article  PubMed  CAS  Google Scholar 

  45. Gottlieb AB (1988) Immunologic mechanisms in psoriasis. J Am Acad Dermatol 18: 1376–1380

    PubMed  CAS  Google Scholar 

  46. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1: 442–447

    Article  PubMed  CAS  Google Scholar 

  47. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43: 595–604

    Article  PubMed  CAS  Google Scholar 

  48. Grandjean I, Duban L, Bonney EA, Corcuff E, Di Santo JP, Matzinger P, Lantz O (2003) Are major histocompatibility complex molecules involved in the survival of naive CD4+ T cells? J Exp Med 198: 1089–1102

    Article  PubMed  CAS  Google Scholar 

  49. Guilhou JJ, Meynadier J, Clot J (1978) New concepts in the pathogenesis of psoriasis. Br J Dermatol 98: 585–592

    PubMed  CAS  Google Scholar 

  50. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, Kwok PY, Menter A, Bowcock AM (2003) A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 35: 349–356

    Article  PubMed  CAS  Google Scholar 

  51. Heng MC, Kloss SG, Kuehn CS, Chase DG (1985) The sequence of events in psoriatic plaque formation after tape-stripping. Br J Dermatol 112: 517–532

    PubMed  CAS  Google Scholar 

  52. Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32: 982–986

    Article  PubMed  CAS  Google Scholar 

  53. Hicke BJ, Watson SR, Koenig A, Lynott CK, Bargatze RF, Chang YF, Ringquist S, Moon-McDermott L, Jennings S, Fitzwater T, Han HL, Varki N, Albinana I, Willis MC, Varki A, Parma D (1996) DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J Clin Invest 98: 2688–2692

    PubMed  CAS  Google Scholar 

  54. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, Catron D, Buchanan ME, Muller A, de Waal MR, Deng G, Orozco R, Ruzicka T, Lehmann P, Lebecque S, Caux C, Zlotnik A (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164: 6621–6632

    PubMed  CAS  Google Scholar 

  55. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A (2002) CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 8: 157–165

    Article  PubMed  CAS  Google Scholar 

  56. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO (1999) IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 162: 7480–7491

    PubMed  CAS  Google Scholar 

  57. International Psoriasis Genetics Study (2003) Assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet 73: 430–437

    Google Scholar 

  58. Jones JL, Berth-Jones J, Fletcher A, Hutchinson PE (1994) Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis. J Pathol 174: 77–82

    Article  PubMed  CAS  Google Scholar 

  59. Jowitt SN, Yin JA (1990) Psoriasis and bone marrow transplantation. BMJ 300: 1398–1399

    Article  PubMed  CAS  Google Scholar 

  60. Kanamori H, Tanaka M, Kawaguchi H, Yamaji S, Fujimaki K, Tomita N, Fujisawa S, Ishigatsubo Y (2002) Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 71: 41–44

    Article  PubMed  Google Scholar 

  61. Kess D, Peters T, Zamek J, Wickenhauser C, Tawadros S, Loser K, Varga G, Grabbe S, Nischt R, Sunderkotter C, Muller W, Krieg T, Scharffetter-Kochanek K (2003) CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 171: 5697–5706

    PubMed  CAS  Google Scholar 

  62. Kragballe K, Duell EA, Voorhees JJ (1986) Selective decrease of 15-hydroxyeicosatetraenoic acid (15-HETE) formation in uninvolved psoriatic dermis. Arch Dermatol 122: 877–880

    Article  PubMed  CAS  Google Scholar 

  63. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1–23

    Article  PubMed  Google Scholar 

  64. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD (1984) Psoriasis. J Am Acad Dermatol 11: 937–947

    PubMed  CAS  Google Scholar 

  65. Krummel MF, Davis MM (2002) Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol 14: 66–74

    Article  PubMed  CAS  Google Scholar 

  66. Kulke R, Bornscheuer E, Schluter C, Bartels J, Rowert J, Sticherling M, Christophers E (1998) The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110: 90–94

    Article  PubMed  CAS  Google Scholar 

  67. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004–2013

    Article  PubMed  CAS  Google Scholar 

  68. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125–130

    PubMed  CAS  Google Scholar 

  69. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022

    Article  PubMed  CAS  Google Scholar 

  70. Leung DY, Walsh P, Giorno R, Norris DA (1993) A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 100: 225–228

    Article  PubMed  CAS  Google Scholar 

  71. Lowe PM, Lee ML, Jackson CJ, To SS, Cooper AJ, Schrieber L (1995) The endothelium in psoriasis. Br J Dermatol 132: 497–505

    PubMed  CAS  Google Scholar 

  72. Mansbridge JN, Knapp AM (1987) Changes in keratinocyte maturation during wound healing. J Invest Dermatol 89: 253–263

    Article  PubMed  CAS  Google Scholar 

  73. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169: 2818–2822

    PubMed  CAS  Google Scholar 

  74. Matzinger P (2002) The danger model: a renewed sense of self. Science 296: 301–305

    Article  PubMed  CAS  Google Scholar 

  75. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385–390

    PubMed  CAS  Google Scholar 

  76. Mehlis SL, Gordon KB (2003) The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 49: S44–S50

    Article  PubMed  Google Scholar 

  77. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178: 211–222

    Article  PubMed  CAS  Google Scholar 

  78. Morhenn VB (1988) Keratinocyte proliferation in wound healing and skin diseases. Immunol Today 9: 104–107

    Article  PubMed  CAS  Google Scholar 

  79. Nathan C (2002) Points of control in inflammation. Nature 420: 846–852

    Article  PubMed  CAS  Google Scholar 

  80. Nestle FO, Turka LA, Nickoloff BJ (1994) Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 94: 202–209

    PubMed  CAS  Google Scholar 

  81. Nickoloff BJ (1991) The cytokine network in psoriasis. Arch Dermatol 127: 871–884

    PubMed  CAS  Google Scholar 

  82. Nickoloff BJ (1999) The immunologic and genetic basis of psoriasis. Arch Dermatol 135: 1104–1110

    PubMed  CAS  Google Scholar 

  83. Nickoloff BJ (2001) Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol 28: 57–64

    Article  PubMed  CAS  Google Scholar 

  84. Nickoloff BJ, Naidu Y (1994) Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 30: 535–546

    PubMed  CAS  Google Scholar 

  85. Nickoloff BJ, Wrone-Smith T (1997) Animal models of psoriasis. Nat Med 3: 475–476

    Article  PubMed  CAS  Google Scholar 

  86. Nickoloff BJ, Wrone-Smith T (1998) Superantigens, autoantigens, and pathogenic T cells in psoriasis. J Invest Dermatol 110: 459–460

    PubMed  CAS  Google Scholar 

  87. Nickoloff BJ, Wrone-Smith T (1999) Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 155: 145–158

    PubMed  CAS  Google Scholar 

  88. Nickoloff BJ, Lewinsohn DM, Butcher EC, Krensky AM, Clayberger C (1988) Recombinant gamma interferon increases the binding of peripheral blood mononuclear leukocytes and a Leu-3+ T lymphocyte clone to cultured keratinocytes and to a malignant cutaneous squamous carcinoma cell line that is blocked by antibody against the LFA-1 molecule. J Invest Dermatol 90: 17–22

    PubMed  CAS  Google Scholar 

  89. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, Kunkel SL, Dixit VM (1991) Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138: 129–140

    PubMed  CAS  Google Scholar 

  90. Nickoloff BJ, Mitra RS, Green J, Shimizu Y, Thompson C, Turka LA (1993) Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J Dermatol Sci 6: 127–133

    Article  PubMed  CAS  Google Scholar 

  91. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM (1995) Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146: 580–588

    PubMed  CAS  Google Scholar 

  92. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24: 212–225

    Article  PubMed  CAS  Google Scholar 

  93. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag U, Dorner AJ, Krueger JG, Trepicchio WL (2001) Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 1: 272–287

    PubMed  CAS  Google Scholar 

  94. Ohta Y, Hamada Y, Katsuoka K (2001) Expression of IL-18 in psoriasis. Arch Dermatol Res 293: 334–342

    Article  PubMed  CAS  Google Scholar 

  95. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876–887

    Article  PubMed  CAS  Google Scholar 

  96. Raychaudhuri SP, Rein G, Farber EM (1995) Neuropathogenesis and neuropharmacology of psoriasis. Int J Dermatol 34: 85–693

    Google Scholar 

  97. Raychaudhuri SP, Dutt S, Raychaudhuri SK, Sanyal M, Farber EM (2001) Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br J Dermatol 144: 931–939

    PubMed  CAS  Google Scholar 

  98. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145: 438–445

    Article  PubMed  CAS  Google Scholar 

  99. Reynolds NJ, Al Daraji WI (2002) Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 27: 555–561

    Article  PubMed  CAS  Google Scholar 

  100. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG (2001) Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alpha-Ebeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81: 335–347

    PubMed  CAS  Google Scholar 

  101. Ruckert R, Asadullah K, Seifert M, Budagian VM, Arnold R, Trombotto C, Paus R, Bulfone-Paus S (2000) Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 165: 2240–2250

    PubMed  CAS  Google Scholar 

  102. Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L (1985) Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 230: 669–672

    PubMed  CAS  Google Scholar 

  103. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426: 454–460

    Article  PubMed  CAS  Google Scholar 

  104. Scheinfeld N (2003) Adalimumab (HUMIRA): a review. J Drugs Dermatol 2: 375–377

    PubMed  Google Scholar 

  105. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Buschenfelde KH, Fleischer B (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102: 145–149

    Article  PubMed  CAS  Google Scholar 

  106. Schon MP (1999) Animal models of psoriasis — what can we learn from them? J Invest Dermatol 112: 405–410

    Article  PubMed  CAS  Google Scholar 

  107. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm KD, Schramm M, Henninger K, Kaufmann R, Gollnick HP, Parker CM, Boehncke WH (2002) Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 8: 366–372

    PubMed  CAS  Google Scholar 

  108. Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M, Good MF, Valdimarsson H, Jonsdottir I (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45: 688–697

    Article  PubMed  CAS  Google Scholar 

  109. Smith CA, Davis T, Wignall JM, Din WS, Farrah T, Upton C, McFadden G, Goodwin RG (1991) T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 176: 335–342

    Article  PubMed  CAS  Google Scholar 

  110. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, Waal-Malefyt RR, Bazan F, Kastelein RA, Liu YJ (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3: 673–680

    PubMed  CAS  Google Scholar 

  111. Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD (1998) Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 111: 1072–1078

    Article  PubMed  CAS  Google Scholar 

  112. Travers JB, Hamid QA, Norris DA, Kuhn C, Giorno RC, Schlievert PM, Farmer ER, Leung DY (1999) Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest 104: 1181–1189

    PubMed  CAS  Google Scholar 

  113. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, Barker JN (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6: 813–820

    Article  PubMed  CAS  Google Scholar 

  114. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Krueger JG (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104: 1527–1537

    PubMed  CAS  Google Scholar 

  115. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993) The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101: 701–705

    Article  PubMed  CAS  Google Scholar 

  116. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L (1995) Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16: 145–149

    Article  PubMed  CAS  Google Scholar 

  117. Van De Kerkhof PC (2000) Neutrophils in psoriasis: cause or effect? Clin Exp Dermatol 25: 165

    Google Scholar 

  118. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PW, Baadsgaard O, van de Winkel JG (2003) Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 112: 1571–1580

    Article  PubMed  CAS  Google Scholar 

  119. Vollstedt S, Franchini M, Alber G, Ackermann M, Suter M (2001) Interleukin-12-and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1. J Virol 75: 9596–9600

    Article  PubMed  CAS  Google Scholar 

  120. Voorhees JJ (1977) Pathophysiology of psoriasis. Annu Rev Med 28: 467–473

    Article  PubMed  CAS  Google Scholar 

  121. Weinshenker BG, Bass BH, Ebers GC, Rice GP (1989) Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 20: 1132–1133

    Article  PubMed  CAS  Google Scholar 

  122. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687–692

    Article  PubMed  CAS  Google Scholar 

  123. Werlen G, Hausmann B, Naeher D, Palmer E (2003) Signaling life and death in the thymus: timing is everything. Science 299: 1859–1863

    Article  PubMed  CAS  Google Scholar 

  124. Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98: 1878–1887

    Article  PubMed  CAS  Google Scholar 

  125. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102: 161–168

    Article  PubMed  CAS  Google Scholar 

  126. Yamamoto T, Matsuuchi M, Katayama I, Nishioka K (1998) Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J Dermatol Sci 17: 8–14

    Article  PubMed  CAS  Google Scholar 

  127. Yang H, Wang H, Tracey KJ (2001) HMG-1 rediscovered as a cytokine. Shock 15: 247–253

    PubMed  CAS  Google Scholar 

  128. Zeigler M, Chi Y, Tumas DB, Bodary S, Tang H, Varani J (2001) Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 81: 1253–1261

    PubMed  CAS  Google Scholar 

  129. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH (2002) Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 109: 671–679

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Center, Skin Disease Research Laboratory, Cardinal Bernardin Cancer Center, Loyola University of Chicago, Maywood, IL, USA

    Brian K. Bonish MD

  2. Loyola University Medical Center, Maywood, IL, USA

    Brian J. Nickoloff MD, PhD

Authors
  1. Brian K. Bonish MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian J. Nickoloff MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Dermatology, Loyola University, Stritch School of Medicine, 2160 S. First Ave., Building 112, Room 342, Maywood, IL, 60153, USA

    Kenneth B. Gordon MD

  2. Division of Rheumatology, Northwestern University, Feinberg School of Medicine, 675 N. St. Clair St., Chicago, IL, 60611, USA

    Eric M. Ruderman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bonish, B.K., Nickoloff, B.J. (2005). Psoriasis. In: Gordon, K.B., Ruderman, E.M. (eds) Psoriasis and Psoriatic Arthritis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27190-2_4

Download citation

  • DOI: https://doi.org/10.1007/3-540-27190-2_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21280-5

  • Online ISBN: 978-3-540-27190-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation